Compare Eni SpA (E) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eni SpA vs Merck & Co., Inc. — how do they compare? Eni SpA trades at $56.24 (market cap $79.81B), while Merck & Co., Inc. trades at $144.92 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 4.4× Eni SpA's market cap, and Eni SpA pays the higher dividend (4.39%). Which is the better fit depends on your goals — on Pluang, investors hold Eni SpA for 53 Days and Merck & Co., Inc. for 98 Days on average.
| E | MRK | |
|---|---|---|
Market Cap | $79.81B | $351.28B |
Volume | 365,912 | 7,969,665 |
Sector | Energy | Health |
52-Week High | $57.61 | $156.43 |
52-Week Low | $34.03 | $82.49 |
Typical Hold Time | 53 Days | 98 Days |
Enterprise Value | $104.34B | $398.04B |
Dividend Yield | 4.39% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eni (E) trades at $56.09, up 3.95% on the day, with mixed technical signals showing bearish moving averages but oversold short-term RSI. Fundamentally, the company shows attractive valuation metrics with P/E of 12.87 and EV/EBITDA of 4.18, though revenue has declined from $132.5B in 2022 to $82.2B in 2025. Recent news highlights strategic initiatives including humanoid robotics partnerships and fuel discount programs.
The stock presents value opportunity with strong cash flow generation and dividend yield, but faces headwinds from declining revenue trends and recent earnings misses. Analyst consensus leans cautious with 62% hold ratings, suggesting patience required for operational turnaround despite attractive valuation multiples.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eni SpA
Eni is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, the company produced 0.8 million barrels of liquids and 4.6 billion cubic feet of natural gas per day. At end-2021, Eni held reserves of 6.6 billion barrels of oil equivalent, 49% of which are liquids. The Italian government owns a 30.1% stake in the company. Eni is placing its renewable and low-carbon business in a separate entity, Plentitude
Read more on E →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
